Role of calcium-sensing receptor in mineral ion metabolism and inherited disorders of calcium-sensing

被引:54
作者
Chattopadhyay, Naibedya
Brown, Edward M.
机构
[1] Cent Drug Res Inst, Div Endocrinol, Lucknow 226001, Uttar Pradesh, India
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
calcium homeostasis; parathyroid; kidney; bone; calcimimetic;
D O I
10.1016/j.ymgme.2006.07.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The extracellular calcium-sensing receptor (CaR), a G protein-coupled receptor that resides on the parathyroid cell surface negatively regulates secretion of parathyroid hormone (PTH). The CaR is functionally expressed in bone, kidney, and gut-the three major calcium-translocating organs involved in calcium homeostasis. Further studies are needed to define fully the homeostatic roles of the CaR in tissues that are involved in systemic extracellular calcium [Ca2+](o) homeostasis. The role of the CaR in regulating calcium metabolism has been greatly clarified by the identification and studies of genetically determined disorders that either activate or inactivate the receptor. Antibodies to the CaR that either activate or inactivate it produce syndromes resembling the corresponding genetic diseases. Expression of the CaR is significantly reduced in primary and secondary hyperparathyroidism, which could contribute to the defective [Ca2+](o)-sensing in these conditions. Calcimimetics act as CaR agonists or allosteric activators and thereby potentiate the effects of [Ca2+](o) on parathyroid cell function. This kind of pharmacological manipulation of the CaR is now used for the treatment of hyperparathyroid states, whereby the calcimimetics increase the activation of the CaR at any given level of extracellular calcium. Calcimimetics are also an effective element in the treatment of secondary hyperparathyroidism, particularly in dialysis patients, by virtue of reducing plasma levels of PTH, calcium and phosphate. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:189 / 202
页数:14
相关论文
共 137 条
[81]  
Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323
[82]   Pharmacological regulation of parathyroid hormone secretion [J].
Nemeth, EF .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (23) :2077-2087
[83]   Calcimimetics with potent and selective activity on the parathyroid calcium receptor [J].
Nemeth, EF ;
Steffey, ME ;
Hammerland, LG ;
Hung, BCP ;
Van Wagenen, BC ;
DelMar, EG ;
Balandrin, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :4040-4045
[84]   Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors [J].
Ogata, H ;
Ritz, E ;
Odoni, G ;
Amann, K ;
Orth, SR .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (04) :959-967
[85]  
OH BH, 1993, J BIOL CHEM, V268, P11348
[86]   The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis [J].
Ohashi, N ;
Uematsu, T ;
Nagashima, S ;
Kanamaru, M ;
Togawa, A ;
Hishida, A ;
Uchida, E ;
Akizawa, T ;
Koshikawa, S .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (06) :726-734
[87]   The origin of the parathyroid gland [J].
Okabe, M ;
Graham, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (51) :17716-17719
[88]   FAMILIAL BENIGN HYPERCALCEMIA - HYPERCALCIURIA AND HYPOCALCIURIA IN AFFECTED MEMBERS OF A SMALL KINDRED [J].
PASIEKA, JL ;
ANDERSEN, MA ;
HANLEY, DA .
CLINICAL ENDOCRINOLOGY, 1990, 33 (04) :429-433
[89]   Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism [J].
Peacock, M ;
Bilezikian, JP ;
Klassen, PS ;
Guo, MD ;
Turner, SA ;
Shoback, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (01) :135-141
[90]   Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism [J].
Pearce, S ;
Steinmann, B .
CLINICAL ENDOCRINOLOGY, 1999, 50 (06) :691-693